Back to News
Market Impact: 0.3
ONWARD Medical Reports 250% Revenue Growth As ARC Therapy Pipeline Advances
Source: Nasdaq
Healthcare & BiotechCompany FundamentalsTechnology & Innovation
ONWARD Medical reported first-half 2026 results highlighting strong growth in ARC-EX System sales, progress in its investigational ARC-IM and ARC-BCI platforms, and a strengthened financial position. The update signals improving commercial traction alongside continued development of the company’s neurotechnology pipeline, though no financial figures or guidance were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
ONWD0.72
More News
- AI Debt Binge Is Reordering Risk Hierarchy With Emerging Bonds
- CNBC Daily Open: Apple's new iPhone bends. Bond vigilantes, not so much
- Inside India newsletter: India’s green push aims to boost energy security but exposes China dependency
- Teradyne at Goldman Sachs Communacopia + Technology Conference: ai push widens
- Samsung works to draw iPhone users to its foldables even as Apple enters the market
- Signet (SIG) Q2 2027 Earnings Call Transcript